G
Ghayas C Issa
Researcher at Harvard University
Publications - 110
Citations - 3071
Ghayas C Issa is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 7, co-authored 11 publications receiving 2325 citations. Previous affiliations of Ghayas C Issa include University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial
Abhishek Maiti,Courtney D. DiNardo,Maro Ohanian,Naveen Pemmaraju,Naval Daver,Gautam Borthakur,Farhad Ravandi,Ghayas C Issa,Guillermo Garcia-Manero,Nitin Jain,Tapan M. Kadia,Lucia Masarova,William G. Wierda,Musa Yilmaz,Yesid Alvarado,Elias Jabbour,Nicholas J. Short,Koichi Takahashi,Sanam Loghavi,Keyur Patel,Kathryn S. Montalbano,Sherry Pierce,Carol Bivins,Rohtesh S. Mehta,Gheath Alatrash,Uday R. Popat,Partow Kebriaei,Betul Oran,Elizabeth J. Shpall,Richard E. Champlin,Hagop M. Kantarjian,Marina Konopleva +31 more
TL;DR: In this article , the authors describe long-term outcomes after SCT following treatment on a prospective clinical trial of 10-day decitabine and venetoclax (DEC10-VEN) for treatment-naïve and previously treated AML (NCT03404193).
Journal ArticleDOI
A phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MRD-positive AML and MDS after hypomethylating agent failure.
Nicholas J. Short,Pavan Bachireddy,Xuelin Huang,Hyunsoo Hwang,Xiaohong Leng,Jaehyun Lee,Daniel Nguyen,Guillermo Garcia-Manero,Courtney D. DiNardo,Gautam Borthakur,Tapan M. Kadia,Naval Daver,Ghayas C Issa,Abhishek Maiti,Farhad Ravandi +14 more
TL;DR: Ravandi et al. as discussed by the authors designed a phase II study to evaluate vibecotamab in other low-blast states, including CD123-positive, MRD-positive AML and in MDS or CMML after failure of hypomethylating agents.
Journal ArticleDOI
Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies
Sangeetha Venugopal,Sanam Loghavi,Mark J. Routbort,Fatima Z. Jelloul,Rashmi Kanagal-Shamanna,Sherry Pierce,Ghayas C Issa,Hussein A. Abbas,Koji Sasaki,Koichi Takahashi,Naval Daver,Farhad Ravandi,Hagop M. Kantarjian,Courtney D. DiNardo +13 more
TL;DR: In this article , the clinical and prognostic impact of IDH/TP53 co-mutated acute myeloid leukemia (AML) is not well defined, and patients are treated with either IDH-targeted therapy (IDHi), intensive chemotherapy (IC), or low intensity therapy (LIC).
Journal ArticleDOI
Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia.
Amer M. Zeidan,Amir T. Fathi,Ghayas C Issa,Harry P. Erba,Julie Mackey Ahsan,B Tomkinson,T. Kozlek,Mollie Leoni,Eunice S. Wang +8 more
TL;DR: Ziftomenib is a potent and selective inhibitor that targets the menin-mixed-lineage leukemia (MLL) lysine[K]-specific methyltransferase 2A (KMT2A) interaction driving leukemogenesis in these subtypes as mentioned in this paper .
Journal ArticleDOI
Abstract A41: Single Cell Multiomic Analysis Reveals Association of TP53-mut Loss of Heterozygosity with Primitive Phenotype in Acute Myeloid Leukemia
Edward Ayoub,Vakul Mohanty,Yuki Nishida,Tallie Patsilevas,Mahesh Basyal,Muharrem Muftuoglu,Kenneth S. Chen,Ghayas C Issa,Michael Andreeff +8 more
TL;DR: Ayoub et al. as discussed by the authors used a scDNA+protein multi-omics approach to dissect clonal architecture and provide a link between genotype-phenotype in acute myeloid leukemia (AML).